Jennison Associates LLC Grows Stock Position in Teladoc Health, Inc. $TDOC

Jennison Associates LLC grew its holdings in Teladoc Health, Inc. (NYSE:TDOC) by 58.3% in the 1st quarter, Holdings Channel.com reports. The fund owned 158,832 shares of the health services provider’s stock after buying an additional 58,472 shares during the period. Jennison Associates LLC’s holdings in Teladoc Health were worth $866,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Kera Capital Partners Inc. purchased a new position in shares of Teladoc Health in the 1st quarter valued at approximately $90,000. Allspring Global Investments Holdings LLC acquired a new position in Teladoc Health during the 1st quarter valued at approximately $1,461,000. Calamos Wealth Management LLC acquired a new position in Teladoc Health during the 1st quarter valued at approximately $282,000. Principal Financial Group Inc. raised its holdings in shares of Teladoc Health by 22.2% in the first quarter. Principal Financial Group Inc. now owns 718,712 shares of the health services provider’s stock worth $3,917,000 after buying an additional 130,637 shares during the last quarter. Finally, Hsbc Holdings PLC lifted its stake in shares of Teladoc Health by 34.6% during the first quarter. Hsbc Holdings PLC now owns 30,956 shares of the health services provider’s stock worth $162,000 after buying an additional 7,956 shares during the period. Institutional investors and hedge funds own 76.82% of the company’s stock.

Teladoc Health Stock Down 8.2%

NYSE:TDOC opened at $8.91 on Thursday. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.80 and a quick ratio of 2.72. The company’s fifty day moving average price is $7.96 and its 200-day moving average price is $6.50. Teladoc Health, Inc. has a 1-year low of $4.40 and a 1-year high of $9.89. The firm has a market capitalization of $1.61 billion, a P/E ratio of -9.19 and a beta of 2.10.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The business had revenue of $613.85 million for the quarter, compared to analyst estimates of $611.04 million. During the same quarter in the prior year, the firm earned ($0.53) earnings per share. The company’s revenue for the quarter was down 2.5% on a year-over-year basis. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. As a group, equities research analysts anticipate that Teladoc Health, Inc. will post -0.92 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on TDOC. Bank of America boosted their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a report on Tuesday, July 7th. Barclays reduced their target price on Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating for the company in a research note on Thursday, March 26th. Canaccord Genuity Group boosted their price target on Teladoc Health from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday. Citigroup increased their price objective on Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a report on Tuesday, May 5th. Finally, Weiss Ratings upgraded Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Five research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Teladoc Health presently has a consensus rating of “Hold” and a consensus price target of $7.73.

Insider Buying and Selling

In related news, insider Carlos Nueno sold 6,196 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $47,275.48. Following the sale, the insider directly owned 57,671 shares of the company’s stock, valued at $440,029.73. This trade represents a 9.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Fernando M. Rodrigues sold 5,677 shares of Teladoc Health stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $43,315.51. Following the transaction, the insider owned 9,572 shares of the company’s stock, valued at approximately $73,034.36. This represents a 37.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 39,195 shares of company stock worth $299,058. Corporate insiders own 0.70% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.